Case Study Role of DPP-4 Inhibitors

Slides:



Advertisements
Similar presentations
Treatment Advances in Type 2 Diabetes Panhandle Nurse Practitioner Symposium April 11, 2015 Dr. Caleb Kim.
Advertisements

Journal Club 埼玉医科大学 総合医療センター 内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University Sellami Mnif Houda.
Type 2 diabetes treatment: Old and New Emily Szmuilowicz, MD, MS Assistant Professor of Medicine Division of Endocrinology Northwestern University.
Adding Prandial Insulin to Basal Insulin: Key Challenges
Supporting the Rationale for the Use of Dapagliflozin as an Add-on to Poorly Controlled Patients on Saxagliptin and Metformin Zachary Bloomgarden, MD Clinical.
Primary Care Prescribing for Type 2 Diabetes Dr. David Jenkins Worcestershire Royal Hospital.
Guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association CHOICE OF AGENT AFTER INITIAL METFORMIN.
A Tale of New Drugs Rebecca Nick-Dart, PharmD, BCPS Clinical Pharmacy Specialist
Diabetes Learning Event 7th October 2016
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Mikhail Kosiborod, MD Professor of Medicine (Cardiology)
Taieb V, et al. Value Health Nov;18(7):A598.
Antihyperglycemic Agents and Renal Function
Diabetes 2017 & Into The Future
SAVOR-TIMI 53 Summary SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke.
Empagliflozin (Jardiance®)
CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?
SGLT2 Inhibitors: What Do the Data Mean for My Patients?
Case 53-year-old Black Man
Updates on Emerging GLP-1 Receptor Agonists
Updates on CVOT Data and Clinical Comparisons That Matter
SGLT2 Inhibitors and Their Clinical Impact:
Global Projections for Diabetes:
Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?
EFFICACY AND MECHANISM
Updates on Outcomes for Novel T2D Therapies
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
SGLT2 Inhibitors in Phase 3 Trials
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Updates Abound.
Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.
How Effective Is Fixed-Dose Combination Therapy in T2D and Where Does It Fit?
Clinical Application of New CV Outcomes Data
T2DM and CV Outcomes Trials: A Deep Dive!
A Deep Dive Into CVOTs.
Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.
ADA/EASD Position Statement: Approach to Hyperglycemia Management
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.
SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.
2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.
Early and Intensive T2D Management:
Breaking Down the CVOTs
Antihyperglycemic therapy in type 2 diabetes: general recommendations
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
Type 2 Diabetes Management:  Where Are We Heading in Our Efforts to Control CV Risk?
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
LEADER One Year On.
Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.
Learning Objectives Metabolic Abnormalities Associated With T2D.
Antihyperglycemic Therapy
T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
The Role of the Kidney in Glucose Control
Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.
Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.
Add-On Therapy to Insulin in T1DM Management
Patient Selection for Modern T2D Agents
Improving Overall Health
2015 EASD In Review: CV Risk management in t2dm
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
Glucose-lowering medication in type 2 diabetes: overall approach.
What's New in Oral Combination Therapy for Type 2 Diabetes?
Emerging Advances in Reducing Renal Complications of T2D
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
Renal licences of commonly used anti-diabetes drugs
Antihyperglycemic therapy in adults with type 2 diabetes
The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum
Presentation transcript:

Case Study Role of DPP-4 Inhibitors

Case Discussion

Case Study Role of Fixed-dose Combination SGLT2/DPP-4 Inhibitor 12/7/2018 9:23 AM Case Study Role of Fixed-dose Combination SGLT2/DPP-4 Inhibitor

Case Discussion

HbA1c Efficacy of Combination Empagliflozin and Linagliptin and Metformin

HbA1c Efficacy of Combination Dapagliflozin and Saxagliptin and Metformin

Combination SGLT2/DPP-4 Inhibitor in Treatment-Naïve Patients

CV Outcome Trials DPP-4 Inhibitors

CV Outcome Trials SGLT2 Inhibitors

Safety SGLT2 Inhibitors

Case Study Role of GLP-1 Agonists

Case Discussion

12/7/2018 9:23 AM “I am an old man and have known many troubles, but most of them never happened.” Mark Twain

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.